Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Global Premature Ejaculation Treatment Market 2017-2021 - Key vendors are Absorption Pharmaceuticals, Bayer, Eli Lilly & Regent Pacific Group - Research and Markets

Research and Markets
Posted on: 22 Nov 17

The "Global Premature Ejaculation Treatment Market 2017-2021" report has been added to Research and Markets' offering.

The global premature ejaculation treatment market to grow at a CAGR of 8.71% during the period 2017-2021.

Global Premature Ejaculation Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The global premature ejaculation treatment market has witnessed the increased use of off-label drugs belonging to different drug classes such as SSRIs (fluvoxamine, paroxetine, sertraline, and fluoxetine) and PDE5 inhibitors (Cialis, VIAGRA, and Levitra). Pharmacological modification of the ejaculatory response in patients with the condition represents a novel approach for the treatment of premature ejaculation and will lead to the gradual replacement of psychosexual counseling, which was previously regarded as the cornerstone of premature ejaculation treatment.

Key Market Trends

  • Growing online retail sales of drugs
  • Increase in awareness of premature ejaculation
  • New treatment methods

Key vendors

  • Absorption Pharmaceuticals
  • Bayer
  • Eli Lilly
  • Regent Pacific Group

Other prominent vendors

  • Dong-A Pharmaceutical
  • Emcure
  • Futura Medical
  • GlaxoSmithKline
  • NeuroHealing Pharmaceuticals
  • Pfizer

Key Topics Covered:

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Premature Ejaculation: Disease Overview

Part 06: Market Landscape

Part 07: Pipeline Landscape

Part 08: Market Segmentation By Route Of Administration

Part 09: Market Segmentation By Drug Class

Part 10: Regional Landscape

Part 11: Decision Framework

Part 12: Drivers And Challenges

Part 13: Market Trends

Part 14: Vendor Landscape

Part 15: Key Vendor Analysis

Part 16: Appendix

For more information about this report visit https://www.researchandmarkets.com/research/5ztq8j/global_premature

View source version on businesswire.com: http://www.businesswire.com/news/home/20171122005255/en/

Business Wire
www.businesswire.com

Last updated on: 22/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.